Indian Journal of Public Health Research & Development

  • Year: 2019
  • Volume: 10
  • Issue: 7

The Serum Micro RNA-375 Utility to Diagnosis of Men with Prostate Cancer in Iraq

  • Author:
  • Kadhum J. Mowayeiz1,, Najat Abudlrazzaq Hasan1, Alaa G. Hussein2, Estabraq AR. Al-Wasiti1, Usama S. Al-Nasiri3
  • Total Page Count: 6
  • Page Number: 1425 to 1430

1Department of Chemistry and Biochemistry, College of Medicine, Al-Nahrain University, Baghdad, Iraq

2Department of Clinical Pathology, College of Medicine, Al-Nahrain University, Baghdad, Iraq

3Scientific Council of Urology Iraqi Board of Medical Specialty

*Correspondence Author: Kadhum J. Mowayeiz, Department of Chemistry and Biochemistry, College of Medicine, Al-Nahrain University, Baghdad, Iraq Phone: +9647705216322 Email: kadum_iraq2003@yahoo.com

Online published on 19 August, 2019.

Abstract

Quantify the level of miRNAs (375) in serum of men with prostatic carcinoma in relation to different Histopathological grade (Gleason score)

This case control study 140 of males with an age range of 40–85 years was conducted divided on Prostate cancer newly diagnostic 35 cases and 35 of Prostate cancer patients under hormonal therapy cases and 35 benign Prostate hyperplasia (BPH) newly diagnosed patients and 35 apparently healthy control subjects.

There were a statistical trend towards increased in serum levels of Prostate specific antigen (tPSA, fPSA) also decreased %FPSA ratio in both Pca patients and HT-Pca as compared with BPH, control samples (p<0.001). And increased in miR-375 expression in both Pca patients and HT-Pca when compared with benign prostatic hyperplasia and control groups (p<0.001). The median fold change level of serum exosomal miR-375 expression were significantly highly (up-regulated) in Pca patients when comparable whit BPH group and healthy control (p<0.001).

The miRNA levels are a direct reflection of their expression in Pca. There was Positive correlation between miRNAs expression in serum samples and clinicopathological parameters such as tumor TNM stage and Gleason score and biochemical marker as prostate specific antigen (tPSA and fPSA).

Keywords

miRNA, prostate cancer, PSA, Gleason score, marker